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Antagonism of N -methyl-D-aspartate (NMDA) receptors by phencyclidine (PCP) is thought
to underlie its ability to induce a schizophrenia-like syndrome in humans, yet evidence
indicates it has a broader pharmacological proﬁle. Our previous lesion studies highlighted
a role for serotonergic projections from the median, but not dorsal, raphe nucleus in
mediating the hyperlocomotor effects of PCP, without changing the action of the more
selective NMDA receptor antagonist, MK-801. Here we compared locomotor responses
to PCP and MK-801 in rats that were administered 5,7-dihydroxytryptamine (5,7-DHT)
into either the dorsal or ventral hippocampus, which are preferentially innervated by
median and dorsal raphe, respectively. Dorsal hippocampus lesions potentiated PCP-
induced hyperlocomotion (0.5, 2.5 mg/kg), but not the effect of MK-801 (0.1 mg/kg).
Ventral hippocampus lesions did not alter the hyperlocomotion elicited by either compound.
Given that PCP and MK-801 may induce different spatiotemporal patterns of locomotor
behavior, together with the known role of the dorsal hippocampus in spatial processing,
we also assessed whether the 5,7-DHT-lesions caused any qualitative differences in
locomotor responses. Treatment with PCP or MK-801 increased the smoothness of the
path traveled (reduced spatial d) and decreased the predictability of locomotor patterns
within the chambers (increased entropy). 5,7-DHT-lesions of the dorsal hippocampus did
not alter the effects of PCP on spatial d or entropy – despite potentiating total distance
moved – but caused a slight reduction in levels of MK-801-induced entropy.Taken together,
serotonergic lesions targeting the dorsal hippocampus unmask a functional differentiation
of the hyperlocomotor effects of PCP and MK-801. These ﬁndings have implications for
studies utilizing NMDA receptor antagonists in modeling glutamatergic dysfunction in
schizophrenia.
Keywords: serotonin, hippocampus, phencyclidine, MK-801, 5,7-dihydroxytryptamine, locomotor hyperactivity,
spatial d, entropy
INTRODUCTION
Phencyclidine (PCP) and MK-801 are often used interchange-
ably in the psychopharmacological literature as they are both
non-competitive antagonists of the glutamatergic N-methyl-D-
aspartate (NMDA) receptor. It is well-established, however, that
MK-801 is more potent at this receptor site than PCP, and that
both agents have direct, and dissimilar, effects on other neu-
rotransmitter systems (Lodge and Johnson, 1990; Morris et al.,
2005). For example, PCP is a more potent catecholaminergic
reuptake inhibitor than MK-801 (Snell et al., 1988; Hiramatsu
et al., 1989) and is reported to block reuptake at the serotonin
transporter (Hiramatsu et al., 1989; Rothman, 1994; Millan et al.,
1999). More recent in vitro binding studies distinguish PCP and
MK-801 by their relative afﬁnities to the dopamine D2 receptor
(Kapur and Seeman, 2002; Seeman et al., 2005), although negative
ﬁndings have also been reported (Millan et al., 1999; Jordan et al.,
2006). It is also suggested that PCP has moderate afﬁnity for the
serotonin 5-HT2A receptor (Kapur and Seeman, 2002) but this has
not been replicated by other studies (Millan et al., 1999; Rabin
et al., 2000).
The functional mechanism of action of PCP and its analog,
ketamine, is of great interest as they are able to evoke a syndrome in
humans resembling the spectrum of symptoms in schizophrenia.
These “dissociative anesthetics” are thus distinct from psychos-
timulants like amphetamine, as they can induce not only positive
symptoms but also the negative symptoms and cognitive deﬁcits
characteristic of the illness (Luby et al., 1959; Krystal et al., 1994;
Halberstadt, 1995; Jentsch and Roth, 1999; Morris et al., 2005).
Moreover, while psychostimulants typically require chronic use
to elicit psychotic states in healthy subjects, a single dose of a
PCP or ketamine can induce schizophrenia-like behavioral dis-
turbances (Abi-Saab et al., 1998; Moghaddam and Jackson, 2003;
Stone and Pilowsky, 2006). Indeed, their pharmacological char-
acterisation as NMDA receptor antagonists in the 1980s (Anis
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et al., 1983; Lodge and Johnson, 1990) led to the development of
the “NMDA receptor hypofunction hypothesis of schizophrenia,”
which suggests that dopaminergic dysfunction may be secondary
to a primary glutamatergic deﬁcit (Jentsch and Roth, 1999; Olney
et al., 1999; Svensson, 2000; Javitt, 2004; Coyle, 2006). The ubiq-
uitous distribution of glutamatergic neurons in the brain, and
their regulation by neuromodulatory transmitters, make them
a likely candidate for dysfunction in schizophrenia. Interactions
between the glutamate system and the dopamine or serotonin sys-
tems have been widely studied in this context (Aghajanian and
Marek, 2000; Svensson, 2000; Coyle, 2006; Meltzer et al., 2011).
However, while PCP may be an appropriate pharmacological tool
used in modeling the disorder (Lipska and Weinberger, 2000;
Morris et al., 2005), whether its schizophrenia-like effects are due
entirely to NMDA receptor antagonism remains to be determined
(Kapur andSeeman,2002; Seeman et al., 2005; Seeman andLasaga,
2005).
Previous studies have provided evidence of differential sero-
tonergic involvement in the hyperlocomotor effects of PCP and
MK-801. For example, PCP-induced locomotor behavior in rats is
attenuated by the administration of 5-HT2A receptor antagonists
(Maurel-Remy et al., 1995; Krebs-Thomson et al., 1998; Millan
et al., 1999). In contrast, 5-HT2A receptor blockade has less con-
sistent effects on MK-801-elicited hyperactivity (Maj et al., 1996;
Higgins et al., 2003), suggesting subtle differences in the mech-
anism of action of these NMDA receptor antagonists. Indeed,
when administered alone, locomotor behaviors such as forward
ambulation and stereotypic movements induced by PCP andMK-
801 are qualitatively different (Hiramatsu et al., 1989; Tricklebank
et al., 1989; Lehmann-Masten andGeyer, 1991; Danysz et al., 1994;
Ogren and Goldstein, 1994; Gilmour et al., 2009). Some suggest
that this is mediated by the ability of PCP to increase serotonin
turnover (Hiramatsu et al., 1989), yet others have reported that
MK-801 alters serotonin turnover but not PCP (Martin et al.,
1998b). Both PCP- and MK-801-induced locomotor hyperactiv-
ity, however, is enhanced by pre-treatment with a 5-HT2C receptor
antagonist (Hutson et al., 2000). In fact, the 5-HT2C receptor is
emerging as a key serotonin receptor subtype involved in themod-
ulation of locomotor behaviors (Takahashi et al., 2001; Giorgetti
and Tecott, 2004; Halberstadt et al., 2009). Serotonergic projec-
tions to the hippocampus, in particular, are implicated in the
modulation of locomotion (Takahashi et al., 2000; Kusljic and van
den Buuse, 2004; Dias Soares et al., 2007) and the 5-HT2 receptor
family seems especially involved in this region (Takahashi et al.,
2001; Dave et al., 2004).
We have extensively studied the role of brain serotonin in
models of schizophrenia in rats using the approach of selec-
tive lesions. Injection of the serotonergic neurotoxin, 5,7-
dihydroxytryptamine (5,7-DHT), into the median, but not the
dorsal, raphe nucleus (MnR, DR) was found to potentiate PCP-
induced locomotor behaviors (Kusljic et al., 2003, 2005), but not
the effect of MK-801 (Kusljic et al., 2005), providing evidence of
a pharmacological distinction between these drugs at the level of
serotonergic projections originating in the MnR. Local 5,7-DHT
administration into MnR projection regions revealed that lesions
of the dorsal, but not ventral, hippocampus enhanced both PCP-
and ketamine-induced hyperlocomotion (Kusljic and van den
Buuse, 2004; Adams et al., 2009). Taken together, these ﬁndings
raised questions about both the selectivity and sensitivity of lesion
effects. Speciﬁcally, we wanted to clarify: (1) whether 5,7-DHT-
lesions of the dorsal hippocampus are sufﬁcient to distinguish
between the actions of PCP and MK-801, like MnR lesions; and
(2) whether the lesions also enhance locomotor responses to PCP
at a ﬁve-fold lower dose. To this end, our ﬁrst experiment inves-
tigated both dorsal and ventral hippocampal lesion effects on
locomotor hyperactivity induced by 0.5 and 2.5 mg/kg of PCP
or 0.1 mg/kg of MK-801.
In addition, we wished to examine more qualitative aspects
of locomotor behavior using a novel method of analyses. Pre-
viously, such high resolution approaches have shown that PCP
and MK-801 induce different spatiotemporal patterns of loco-
motor behavior (Lehmann-Masten and Geyer, 1991), and that
pre-treatment with serotonin receptor ligands modulates the type
of patterns elicited by PCP, creating an entirely new behavioral
proﬁle (Krebs-Thomson et al., 1998). Therefore, we conducted a
second experiment focusing on more qualitative aspects of loco-
motor responses to PCP (2.5 mg/kg) and MK-801 (0.1 mg/kg)
in dorsal hippocampus lesioned rats, including the “smoothness”
and“predictability”of locomotor paths. Given the prominent role
of the dorsal hippocampus in spatial information processing, with
visuospatial inputs directed mainly to the dorsal, but not ven-
tral, domain (Moser and Moser, 1998; Small, 2002; Bast, 2007),
we anticipated our lesions might modulate such spatial aspects of
locomotor behavior, either at baseline or followingdrug treatment.
MATERIALS AND METHODS
ANIMALS
Sixty four male Sprague-Dawley rats (aged 4–5 weeks) were
obtained from the Department of Pathology, University of
Melbourne (Parkville,VIC,Australia), orMonashAnimal Services
(Clayton, VIC, Australia). Colony conditions were standardized,
with a 12/12 h light/dark cycle (lights on 7:00–19:00) and the tem-
perature maintained at approximately 22◦C. All procedures were
performed in the light phase. Rats were housed in groups of 2–3
in cages enriched with shredded paper and cardboard boxes, with
standard food and tap water available ad libitum. All surgical and
experimental protocols were approved by the Animal Experimen-
tation Ethics Committee of the University of Melbourne or the
Howard Florey Institute (Parkville, VIC, Australia), and adhered
to the guidelines outlined in theAustralian Code of Practise for the
Care and Use of Animals for Scientiﬁc Purposes (National Health
and Medical Research Council of Australia, 2004).
DRUGS AND SOLUTIONS
To prevent oxidation, 5,7-DHT (5,7-dihydroxytryptamine crea-
tinine sulfate salt, Fluka BioChemika, Sigma-Aldrich, St. Louis,
MO, USA) was dissolved in 0.9% saline containing 0.1% ascorbic
acid. The selective noradrenaline reuptake inhibitor, desmethylim-
ipramine hydrochloride (DMI; Sigma-Aldrich), was prepared in
distilled water and dissolved by sonication. The non-steroidal
anti-inﬂammatory agent, Carprofen (Rimadyl®, 50 mg/ml, Pﬁzer,
West Ryde, NSW, Australia) was diluted in 0.9% saline. Con-
sistent with previous work in our laboratory, PCP hydrochlo-
ride (Experiment 1: Sigma-Aldrich; Experiment 2: National
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Measurement Institute, Pymble, NSW, Australia) and (+)-MK-
801 hydrogenmaleate (dizocilpine, Sigma-Aldrich) were dissolved
in 0.9% saline and administered subcutaneous (s.c.). All doses
were taken as the weight of the salt and injection volume was
1 mg/kg body weight.
STEREOTAXIC LESION SURGERY
Surgery was conducted when animals were 7–8 weeks old as
described previously (Kusljic and van den Buuse, 2004; Adams
et al., 2008, 2009; Adams and van den Buuse, 2011). In brief,
rats were randomly allocated to one of four groups: dor-
sal hippocampus-injected (DHI), ventral hippocampus-injected
(VHI) or their equivalent sham-operated controls. At the outset
of surgery, 30minprior to 5,7-DHT infusion,DMI (20mg/kg, i.p.)
was injected to prevent the destruction of noradrenergic neurons.
Animals were then anesthetized using a 10% isoﬂurane/oxygen
mixture and transferred to a stereotaxic apparatus afﬁxed with a
nose cone to maintain anesthesia. Carprofen (5 mg/kg, s.c.) was
used to minimize post-operative discomfort. Holes were drilled
in the skull above the dorsal or ventral hippocampus, using the
following coordinates relative to bregma: posterior −3.6 mm, lat-
eral ±1.5 and ±3.5 mm, and ventral −3.8 mm for the dorsal
hippocampus; posterior −5.6 mm, lateral ±4.8 mm and ven-
tral −8.0 mm for the ventral hippocampus (Paxinos and Watson,
1998). 5,7-DHT (1 μl, 5 μg/μl) was injected bilaterally into the
dorsal or ventral hippocampus over 2 min; for the DHI infu-
sions, two 0.5μl injectionswere used. Sham-operated rats received
equivalent volumes of vehicle solution. Rats were allowed two
weeks to recover from surgery before behavioral experiments
started.
LOCOMOTOR HYPERACTIVITY TESTING
Locomotor activity was measured in eight automated photocell
cages (43 cm × 43 cm × 31 cm, l × w × h, ENV-520, Med
Associates Inc., St. Albans, VT, USA). Each cage had 16 evenly-
spaced infrared transmitters and receivers on each of its four sides,
which detected a rat’s position in three dimensions (x, y and z).
Software (Activity Monitor 4.0, Med Associates Inc.) recorded the
status of the infrared beams every 50 ms, effectively generating a
spatio-temporal map of an animal’s movement throughout a test-
ing session. Every 5 min, the software calculated the total distance
moved from these data, reﬂecting the gross distance traveled by an
animal with small repetitive movements ﬁltered out.
Each session included a random allocation of 5,7-DHT-
lesioned rats and sham-operated controls. Baseline locomotor
activity was initially recorded for 30 min, allowing the ani-
mals to habituate to the cages before receiving drug treatment.
Post-injection locomotor activity was then recorded for further
90 min. Testing sessions were separated by 3–4 days to allow for
drug clearance, and the order of treatment in each experiment
was pseudo-randomized to offset potential interactions, such as
sensitisation, that could occur between treatments. Baseline activ-
ity differences were assessed by averaging pre-injection distance
moved across all testing sessions within each experiment. As base-
line activity was unaffected by the serotonergic lesions in both
experiments, these data were subsequently removed from analyses
of drug effects.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
Lesions were conﬁrmed by measuring serotonin levels in the dor-
sal and ventral hippocampus using Serotonin ELISA kits (Labor
Diagnostika Nord GmbH & Co. KG, Nordhorn, Germany), with
minor adjustments as described before (Adams et al., 2009; Adams
and van den Buuse, 2011). Rats were decapitated at least three
days after the end of locomotor testing, and the dorsal and ventral
hippocampi dissected out, weighed, and stored at −80◦C until
ELISA. Serotonin levels were normalized for tissue wet weight.
Analyses of ELISA data from DHI- and VHI-sham-operated rats
in each experiment foundnodifferences in hippocampal serotonin
levels between the two types of controls; therefore, these groups
were combined. In line with our previous work (Adams and van
den Buuse, 2011), DHI or VHI rats were excluded if the percent-
age serotonin depletion was <20% in the relevant hippocampal
domain compared to sham-operated animals; presently, only one
VHI rat was excluded from Experiment 1.
DESIGN AND ANALYSES
Animals were used in two experimental cohorts. Experiment 1
contained DHI (n = 16), VHI (n = 8) and equivalent sham-
operated controls (n = 17); all rats received saline, 0.5 and
2.5 mg/kg PCP, and 0.1 mg/kg MK-801 in locomotor activity
tests. Experiment 2 contained only DHI (n = 12) and DHI-sham-
operated (n = 11) rats; all animals received saline, 2.5 mg/kg PCP
and 0.1 mg/kg MK-801 in locomotor activity tests; 0.02 mg/kg
MK-801 was also tested in these animals yet these data are not pre-
sented as this dose had negligible effect on locomotor responses.
Using awithin-subjects design to assess drug responseswas impor-
tant for comparing the effects of PCP and MK-801 by minimizing
the variation that is inherent in between-group comparisons; in
addition, it greatly reduced the number of animals required.
In Experiment 1, distance moved data were calculated by the
activity monitor software. In Experiment 2, raw x, y, t data were
extracted from the software as ASCII text ﬁles and analyzed for
qualitative aspects of locomotor activity. Analysis of the spatial
structure of locomotor paths was performed by calculating the
descriptive statistic, spatial d. As described by Paulus and Geyer
(1991), spatial d is based conceptually on fractal geometry and
calculated using scaling arguments. Changes in d reﬂect smoother
(reduced d values) or rougher (increased d values) locomotor
paths. Entropy was used to quantify the predictability of locomo-
tor paths, speciﬁcally the predictability of sequences of transitions
across different zones of the test chamber (Paulus and Geyer,
1993). For example, a rat repeatedly circling along the outer edges
of the chamber would move through zones 1, 2, 3, 6, 9, 4, and
back to 1; repetition of this sequence many times would result in
a low entropy measure. By contrast, a rat that moves through dif-
ferent zones of the chamber via more diverse routes would result
in higher entropy levels.
Analysis of variance (ANOVA) with repeated measures, as
appropriate, was used to compare differences between and within
groups using SYSTAT software (SYSTAT 9.0, SPSS Inc., Chicago,
IL, USA). All data were analyzed separately, initially in an overall
ANOVA with data from each group (Experiment 1: sham-
operated, DHI, VHI; Experiment 2: sham-operated, DHI). When
signiﬁcant main effects of, or interactions with, group were found
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in the main analyses, planned (a priori) ANOVA comparisons
ensued, with either DHI orVHI groups compared to controls, and
drug effects compared to that of saline injection.
Distance moved data from Experiment 1 were analyzed in
5-min intervals to assess possible time-dependent drug effects,
whereas distance moved, spatial d and entropy data from
Experiment 2 were assessed in 30-min intervals. Post-injection
spatial d and entropy data were analyzed for 60 min as low activity
levels in the 60–90 min block following saline treatment ren-
dered measurement of these variables unreliable. Thus, overall
ANOVAs of all post-injection activity data contained the repeated
measures variables, “drug” (Experiment 1: four saline/drug treat-
ments; Experiment 2: three saline/drug treatments) and “time”
(Experiment 1: 18 5-min intervals; Experiment 2: two or three
30-min intervals).
Enzyme-linked immunosorbent assay data were analyzed by
comparing absolute serotonin levels in either the dorsal or ventral
hippocampus. Data are presented as percentage depletion relative
to sham-operated animals to control for inter-assay variability.
Differences were considered signiﬁcant if p < 0.05.
RESULTS
SEROTONIN DEPLETION IN THE DORSAL AND VENTRAL HIPPOCAMPUS
In Experiment 1, DHI rats showed a comparable level of serotonin
depletion in the ventral hippocampus as VHI rats, but a greater
extent of depletion in the dorsal hippocampus (Table 1). VHI rats
in this cohort also showed a slight, but signiﬁcant, depletion of
serotonin in the dorsal hippocampus. Like those in Experiment 1,
DHI rats in Experiment 2 showed serotonin depletion in both
the dorsal and ventral hippocampus compared to sham-operated
controls (Table 1).
EXPERIMENT 1: LESION EFFECTS ON LOCOMOTOR HYPERACTIVITY
INDUCED BY 0.5 AND 2.5 mg/kg PCP AND 0.1 mg/kg MK-801
Analysis of variance of average pre-injectiondistancemoved found
no group differences, indicating that 5,7-DHT administration into
the dorsal or ventral hippocampus did not affect levels of base-
line activity (Figure 1). Locomotor activity diminished over this
Table 1 | Serotonin depletion pattern in the dorsal and ventral
hippocampus of 5,7-DHT-lesioned rats.
Dorsal hippocampus Ventral hippocampus
% Depletion F, p % Depletion F, p
Experiment 1
DHI 77 ± 4** 177.0, <0.001 54 ± 5** 34.3, <0.001
VHI 19 ± 8* 5.4, 0.029 45 ± 8* 14.0, 0.001
Experiment 2
DHI 79 ± 5** 130.1, <0.001 82 ± 2** 138.1, <0.001
Data are expressed as mean percentage depletion of serotonin ± SEM in each
hippocampal domain relative to the sham-operated controls in each experiment.
Statistical results in adjacent columns refer to the F- and p-values obtained
in ANOVA comparison of absolute serotonin levels. *p < 0.05, **p < 0.001
compared to sham-operated controls.
FIGURE 1 | Effect of 5,7-DHT-lesions targeting the dorsal or ventral
hippocampus on locomotor hyperactivity induced by 0.5 and
2.5 mg/kg PCP and 0.1 mg/kg MK-801. Panels show mean distance
moved (cm) in 5 min intervals ± SEM for DHI (n = 16), VHI (n = 8) and
sham-operated rats (n = 17) treated with (A) saline (B) 0.5 and
(C) 2.5 mg/kg PCP and (D) 0.1 mg/kg MK-801. Total distance moved
following 0.5 and 2.5 mg/kg PCP injection was signiﬁcantly higher in
DHI rats compared to controls (see text for details).
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30 min pre-injection habituation period similarly in all animals
(main effect of time: F5,190 = 163.5, p < 0.001).
Analysis of all post-injection distance moved data revealed sig-
niﬁcant lesion effects (main effect of group: F2,38 = 3.7, p=0.034;
drug by group interaction: F6,114 = 3.7, p = 0.002; Figure 1). Rats
that were administered 5,7-DHT into the dorsal hippocampus
showed enhanced locomotor hyperactivity following 0.5 mg/kg
PCP treatment, with a 109 ± 37% increase in total post-injection
distance moved compared to controls (main effect of group:
F1,31 = 7.2, p = 0.012; drug by group interaction: F1,31 = 6.0,
p = 0.020; Figure 1B). Conﬁrming our previous ﬁndings (Kusljic
and van den Buuse, 2004), DHI rats also showed potentiated
hyperlocomotor effects of 2.5 mg/kg PCP treatment (51 ± 15%
increase in total distancemoved;main effect of group: F1,31 = 10.6,
p = 0.003; drug by group interaction: F1,31 = 9.3, p = 0.005;
Figure 1C). The enhancement of PCP-induced hyperlocomo-
tion was uniform throughout the session for both doses (lack of
signiﬁcant interactions with time and group; Figures 1B,C). In
contrast, VHI and sham-operated animals showed similar PCP-
induced locomotor hyperactivity at both doses (main effects of
drug: 0.5 mg/kg, F1,23 = 13.4, p = 0.001; 2.5 mg/kg, F1,23 = 133.3,
p< 0.001; Figures 1B,C). Notably, treatmentwithMK-801 evoked
locomotor hyperactivity to a similar extent and temporal magni-
tude in sham-operated, DHI and VHI rats (main effect of drug:
F1,38 = 127.3, p < 0.001; drug by time interaction: F17,646 = 42.3,
p < 0.001), indicating that the potentiated hyperlocomotor effect
in DHI rats is unique to PCP (Figure 1D).
EXPERIMENT 2: FURTHER ANALYSIS OF DORSAL HIPPOCAMPUS
LESION EFFECTS ON LOCOMOTOR HYPERACTIVITY INDUCED BY
2.5 mg/kg PCP AND 0.1 mg/kg MK-801
Distance moved
As observed in Experiment 1, average pre-injection distance
moved did not differ between DHI and sham-operated rats in
this experiment. Both groups habituated to the chambers with
similar levels of activity (Figure 2A).
Analysis of variance of all post-injection distance moved data
found that the effects of drug treatment were, again, dependent on
lesion group (drug by group interaction: F2,42 = 6.3, p = 0.004;
Figure 2A). As expected, total PCP-induced hyperactivity was
greater in DHI rats than in sham-operated controls (51 ± 13%
increase in total distance moved; main effect of group: F1,21 = 8.5,
p = 0.008; drug by group interaction: F1,21 = 11.3, p = 0.003;
Figure 2A,middle panel). In addition,MK-801 treatment caused a
time-dependent increase in locomotor activity that was unaffected
by dorsal hippocampus lesions (main effect of drug: F1,21 = 125.1,
p < 0.001; drug by time interaction: F2,42 = 52.1, p < 0.001;
Figure 2A, bottom panel). The lack of signiﬁcant interactions
between time and group in analyses of distance moved data for
both compounds also correspondedwith Experiment 1. Represen-
tative plots of post-injection activity are provided in Figure 3, in
which enhanced PCP-induced hyperlocomotion in a DHI animal
is clearly depicted (Figure 3B, bottom panel).
Spatial d
Assessment of average pre-injection spatial d revealed no dif-
ference in baseline levels between DHI and sham-operated rats
(Figure 2B). After saline treatment, spatial d values increased
over the course of the test sessions as the animals habituated to
the chambers and made fewer smooth, linear exploratory move-
ments (saline data only, comparison of all three time blocks: main
effect of time, F2,42 = 18.9, p < 0.001; Figure 2B, top panel).
Spatial d values exceeded baseline levels during the 30–60 min
block (F1,21 = 27.7, p < 0.001) but not during the 0–30 min
block.
Overall ANOVA of post-injection data found time-dependent,
drug effects on spatial d that were unaffected by the lesions (main
effect of drug: F2,42 = 45.3, p < 0.001; drug by time interaction:
F2,42 = 46.4, p < 0.001). Compared to saline, both PCP and
MK-801 treatments reduced spatial d in DHI and sham-operated
rats (main effects of drug: PCP, F1,21 = 67.7, p < 0.001; MK-801,
F1,21 = 61.4, p < 0.001), with more pronounced effects occur-
ring in the 30–60 min time block (drug by time interactions:
PCP, F1,21 = 9.5, p = 0.006; MK-801, F1,21 = 82.6, p < 0.001;
Figure 2B). Further analyses for each time block revealed that PCP
treatment reduced spatial d in both blocks (0-30min, F1,21 = 23.5,
p < 0.001; 30–60 min, F1,21 = 75.3, p < 0.001), whereas the
effect of MK-801 treatment was signiﬁcant in the 30–60 min
interval only (0–30 min, F1,21 = 3.6, p = 0.071; 30–60 min,
F1,21 = 135.5, p < 0.001). 5,7-DHT-lesions targeting the dorsal
hippocampus, however, did not inﬂuence the changes in overall
smoothness of the paths traveled following treatment with either
compound.
Entropy
Analysis of mean pre-injection entropy data found no group dif-
ferences, highlighting that the predictably of the paths traveled at
baseline was unchanged by 5,7-DHT administration into the dor-
sal hippocampus (Figure 2C). In saline-treated animals, entropy
values declined over the course of the session as the animals
became habituated to the test chambers, indicating that the loco-
motor paths became progressively more repetitive (saline data
only, comparison of all three time blocks: main effect of time,
F2,42 = 51.6, p < 0.001; Figure 2C, top panel). Entropy levels
were lower than baseline during both post-injection time blocks
(0–30 min, F1,21 = 11.0, p = 0.003; 30–60 min, F1,21 = 103.5,
p < 0.001).
Assessment of all post-injection data found an overall, time-
dependent inﬂuence of drug treatment on entropy levels (main
effect of drug: F2,42 = 34.6, p < 0.001; drug by time interaction:
F2,42 = 35.5, p < 0.001; Figure 2C). Drug effects on entropy
were further inﬂuenced by hippocampal 5,7-DHT lesions (drug
by group interaction: F2,42 = 3.7, p = 0.032). PCP administration
increased entropy compared to saline injection (main effect of
drug: F1,21 = 51.1, p < 0.001), indicating that the animals traveled
in less predictable manner around the chambers. While entropy
levels following saline treatment decreased over time, after PCP
injection entropy was elevated throughout the session (drug by
time interaction: F1,21 = 28.5, p < 0.001; 0–30 min, F1,21 = 8.4,
p= 0.009; 30–60min,F1,21 = 65.1, p< 0.001). This effect was sim-
ilar in sham-operated andDHI animals (Figure 2C,middle panel).
TreatmentwithMK-801 also increased entropy compared to saline
injection (main effect of drug: F1,21 = 36.5, p < 0.001) yet, similar
to its effect on spatial d, this was signiﬁcant only in the 30–60 min
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FIGURE 2 | Effect of 5,7-DHT-lesions targeting the dorsal hippocampus
on qualitative aspects of locomotor hyperactivity induced by 2.5 mg/kg
PCP and 0.1 mg/kg MK-801. Panels show mean (A) distance moved (cm),
(B) spatial d, and (C) entropy in 30 min intervals ± SEM for DHI (n = 12) and
sham-operated rats (n = 11) treated with saline (top), 2.5 mg/kg PCP (middle),
and 0.1 mg/kg MK-801(bottom). Total distance moved following 2.5 mg/kg
PCP injection was, again, signiﬁcantly higher in DHI rats compared to
controls (see text for details). ##p < 0.01, ###p < 0.001 for comparison with
baseline. **p < 0.01, ***p < 0.001 for comparison with saline in respective
time block.
time block (drug by time interaction: F1,21 = 51.4, p < 0.001;
0–30 min, F1,21 = 0.024, p = 0.878; 30–60 min, F1,21 = 64.1,
p < 0.001). Interestingly, compared to sham-operated controls,
overall MK-801-induced enhancement of entropy was reduced
in DHI rats (drug by group interaction: F1,21 = 4.6, p = 0.043;
Figure 2C, bottom panel). Serotonergic lesions targeting the dor-
sal hippocampus, therefore, did not alter the random nature of
locomotor paths traveled following PCP treatment, yet slightly
reduced the extent to which MK-801 treatment increased this
factor.
DISCUSSION
There is considerable interest in the behavioral mechanism of
action of PCP as it can produce a state in healthy humans anal-
ogous to symptoms in schizophrenia. Here we report that rats
with 5,7-DHT-lesions targeting the dorsal hippocampus show
potentiated locomotor hyperactivity following treatment with 0.5
or 2.5 mg/kg PCP, extending our earlier work by showing that
the lesions are also sensitive to a ﬁve-fold lower dose (Kusljic and
van den Buuse, 2004). Given the role of the hippocampus in spa-
tial information processing, we anticipated that enhanced PCP
responses in DHI rats would be associated with changes in the
modulation of spatial d or entropy, yet analysis of behavioral
patterns revealed no lesion effects on these variables at base-
line or following PCP treatment. In contrast to PCP, DHI rats
did not show a parallel enhancement of locomotor responses to
MK-801, but rather a slight, but signiﬁcant, reduction inMK-801-
induced entropy. Thus, like lesions of serotonergic cell bodies in
the MnR (Kusljic et al., 2005), 5,7-DHT-lesions targeting the dor-
sal hippocampus are sufﬁcient to unmask functional differences
between PCP and the more selective NMDA receptor antagonist,
MK-801. Together with data from numerous locomotor activity
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FIGURE 3 | Spatial patterns of locomotor hyperactivity shown by
representative, individual sham-operated (top) and DHI (bottom)
animals. Plots show activity traces in the 60–90 min time block following
treatment with (A) saline (B) 2.5 mg/kg PCP and (C) 0.1 mg MK-801.
Enhanced PCP-induced locomotor hyperactivity in DHI rats is clearly depicted
by the increased density of tracings in the chamber (panel B, bottom).
experiments in 5,7-DHT-lesioned rats (see Adams et al., 2008 for
review; Adams et al., 2009), these results indicate that serotonin
projections from theMnR to the dorsal hippocampus are involved
in the hyperlocomotor mechanism of action of the dissociative
anesthetics, PCP and ketamine, as opposed to that of psychostim-
ulants, like amphetamine, and in amanner seemingly independent
of their ability to block NMDA receptors, or modulate spatial pat-
terns of behavior. Like other reports (Snell et al., 1988; Hiramatsu
et al., 1989; Rothman, 1994; Kapur and Seeman, 2002; Seeman
et al., 2005; Seeman and Lasaga, 2005), our ﬁndings lend strength
to the notion that the schizophrenomimetic effects of PCP and
ketamine may not be due to NMDA receptor antagonism alone.
The differential effects of the lesions on PCP or MK-801-
induced forward locomotion seem to hinge on impaired sero-
tonergic tone in the dorsal hippocampus only, since rats with
ventral hippocampus lesions in Experiment 1 showedno change in
responses to either compound. In addition, dorsal hippocampus
serotonin depletion appears robust in potentiating PCP responses
regardless of the additional depletion observed in the ventral
domain. In our early study, DHI rats showed no secondary lesion
effects in the ventral hippocampus (Kusljic and van den Buuse,
2004); the asymmetric pattern of serotonin depletion observed
in our DHI and VHI rats more recently has been discussed in
detail elsewhere (Adams et al., 2009). However, with reduced sero-
tonin levels in the whole hippocampus, we cannot deﬁnitively
conclude that the behavioral changes are due to 5,7-DHT effects
in the dorsal hippocampus only. Since entropy and spatial d was
not assessed in VHI animals, it is possible that serotonin deple-
tion in both hippocampal domains of DHI rats contributed to the
reduction of MK-801-induced entropy. The ventral hippocampus
also contains so-called “place cells,” involved in creating an inter-
nal representation of the environment (O’Keefe and Dostrovsky,
1971; Sweatt, 2004), suggesting that it, too, participates in spatial
information processing (Moser and Moser, 1998). Nevertheless,
the absence of corresponding functional changes in VHI rats
in Experiment 1, together with our previous work (Kusljic and
van den Buuse, 2004; Adams et al., 2009), suggests that serotonin
depletion in the ventral hippocampus does not largely inﬂuence
drug-induced hyperlocomotion.
Neither dorsal nor ventral hippocampal lesions were found to
alter baseline locomotor behavior. Given that the expression of
motor deﬁcits after 6-hydroxydopamine-lesions depends on lev-
els of dopamine depletion being >80–90% (Koob et al., 1981;
Zigmond et al., 1990), it is possible that overt effects on base-
line behavior were not seen due to insufﬁcient levels of serotonin
depletion. However, some of our previous cohorts have shown
>80–90% depletion of hippocampal serotonin without showing
alterations in baseline activity (Kusljic and van den Buuse, 2004;
Adams et al., 2009). Even so, the utility of the 30 min habituation
phase to assess baseline deﬁcits may be questioned, as activity lev-
els soon become negligible during this periodmaking it difﬁcult to
evaluate any change. Indeed, others report that the extent of dorsal,
but not ventral, hippocampal serotonin depletion correlates with
the amount of activity displayed in the dark phase (Williams and
Azmitia, 1981). Observing our lesioned animals in a novel open
ﬁeld, potentially in the dark phase, as well as incorporating assess-
ments of vertical activity and grooming behavior, may provide a
better appraisal of baseline lesion effects on motor behavior. In
the present studies, as in our previous experiments, the expression
of behavioral changes due to 5,7-DHT-lesions targeting the dorsal
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hippocampus was found to depend on pharmacological challenge
(Adams et al., 2009; Adams and van den Buuse, 2011).
Phencyclidine has previously been shown to produce bipha-
sic effects on spatial patterns of locomotion, generating smoother
paths at 2.25 mg/kg (decreasing d) and reducing the smoothness
of paths (increasing d) at higher doses (6.75, 10.125mg/kg; Krebs-
Thomson et al., 1998). Using the same analytical method, we
similarly found that administration of 2.5 mg/kg PCP decreased d
equally in both control and DHI rats. Interestingly, pre-treatment
with a 5-HT2A/2C agonist potentiated hyperlocomotion and fur-
ther decreased spatial d in rats treated with 2.25 mg/kg PCP
(Krebs-Thomson et al., 1998); together with the current data,
one could speculate that 5-HT2A/2C receptors in the dorsal hip-
pocampus are involved in the former, but not the latter, effect.
Finding that 0.1 mg/kg MK-801 also increases locomotion while
producing smoother locomotor paths (decreasing d), and that
both compounds reduce the predictability of the locomotor paths
traveled (increasing entropy) is novel to this study. Hippocam-
pal NMDA receptors are vital for spatial memory and information
processing, with evidence indicating that they are necessary for the
acquisition, or encoding, of spatial memory but not for retrieval
(Nakazawa et al., 2004; Martin and Clark, 2007). One interpreta-
tionof the increase in entropy followingMK-801orPCP treatment
is that NMDA receptor blockade impairs the animals’ memory of
where they have previously been in the chamber, making them
explore more randomly. In addition, 5,7-DHT-lesions targeting
the dorsal hippocampus selectively reduced the ability of MK-
801 to increase entropy, independent of its effect on locomotor
activity. The mechanism underlying this more subtle effect of
the lesions is unclear, but likely relates to a lesion-induced dys-
regulation of hippocampal NMDA receptors. Since PCP-induced
entropy was not changed by the lesions, this could simply reﬂect
the more potent and selective NMDA antagonist actions of
MK-801.
Treatment with 0.1 mg/kg MK-801 and 2.5 mg/kg PCP pro-
duced equivalent levels of hyperlocomotion in control animals in
both experiments. However, the maximal effect of MK-801 was
seen between 30 and 60 min post-injection followed by a gradual
decrease, while the peak PCP effect occurred earlier, between 15
and 30min. The different times to onset of maximal effect of these
agents corroborate previous studies (Ogren and Goldstein, 1994;
Klamer et al., 2005), and may reﬂect differences in their temporal
association to the NMDA receptor (Ogren and Goldstein, 1994).
Indeed, MK-801 and PCP have similar volumes of distribution
(Schwartz and Wasterlain, 1991; Shelnutt et al., 1999) and indexes
of lipophilicity making them equally brain penetrant (Ault et al.,
1995). In both experiments, however, the time to onset of PCP’s
effects in DHI rats was more rapid, and the effect more vigorous
and longer lasting, which is unlikely to arise from lesion-induced
changes in pharmacokinetics. Instead, altered hyperlocomotor
responses to PCP, and ketamine (Adams et al., 2009), in DHI rats
appear to be a quantitative enhancement of the normal motor
responses to these agents. In control animals, these compounds
may activate serotonergic transmission in the dorsal hippocampus
in amanner such that it inhibits their own effects. Accordingly, the
absence of intact serotonergic tone in the dorsal hippocampus of
DHI rats unmasks this self-activated, inhibitory mechanism. This
could be signiﬁcant to the mechanism of action of these dissocia-
tive compounds, as the lesion-induced enhancement was observed
across all tested doses of PCP (0.5, 2.5 mg/kg) and ketamine (6.25,
12.5, 25 mg/kg; Adams et al., 2009).
Mechanisms within the dorsal hippocampus through which
PCP and ketamine putatively activate serotonergic transmission
could be pre- or post-synaptic, or a combination of both. As
hypothesized earlier (Kusljic and van den Buuse, 2004), the
effect could involve reduced PCP-induced serotonin release in the
dorsal hippocampus (Martin et al., 1998a). Ketamine treatment
increases extracellular serotonin levels in the ventral hippocampus
(Lorrain et al., 2003), yet there is a lack of data regarding its effect
in the dorsal domain. Serotonin release following treatment with
these agents may result directly from SERT reuptake inhibition
(Hori et al., 1996; Nishimura et al., 1998; Millan et al., 1999) or
indirectly via glutamatergic disinhibition (Martin et al., 1998a),
whereby preferential blockade of NMDA receptors on GABAergic
interneurons byNMDA receptor antagonists “disinhibits” cortico-
limbic circuits, causing the release of neurotransmitters (Olney
et al., 1999). It follows, however, that MK-801 treatment would
also disinhibit hippocampal circuits, and it was recently shown
that local infusion of MK-801 increases extracellular serotonin
levels in the dorsal hippocampus (Fallon et al., 2007). An alter-
native mechanism to explain the enhanced PCP responses may
involve post-synaptic changes in serotonergic receptors. Autora-
diography experiments revealed that local 5-HT1A and 5-HT2A
receptor densities are unchanged by the lesions, yet there is a
70% increase in 5-HT2C receptor densities in the dorsal hip-
pocampus of DHI rats (Adams and van den Buuse, 2011). This
ﬁnding is compelling because, unlike systemic administration,
infusion of 5-HT2C receptor agonists into the dorsal hippocam-
pus stimulates locomotor activity (Takahashi et al., 2001; Stiedl
et al., 2007). Thus, a simple explanation for our results would be
a direct action by PCP on an upregulated 5-HT2C receptor pool
in the dorsal hippocampus of DHI rats. However, preliminary in
vitro data indicate that PCP, ketamine or MK-801 do not directly
bind to or activate the human 5-HT2C receptor (unedited INI
5-HT2C receptor isoform; Stewart and Christopoulos, Monash
Institute of Pharmaceutical Sciences, Parkville, VIC, Australia,
unpublished observations). While this does not exclude the pos-
sibility of a direct action on rat 5-HT2C receptors, particularly
in light of evidence that PCP and ketamine act directly on rat
5-HT2A receptors (Nabeshima et al., 1988; Kapur and Seeman,
2002), this would have little relevance to humans. Additional
locomotor behavioral experiments combining the local admin-
istration of selective ligands, such as for 5-HT2 receptor subtypes,
into the dorsal hippocampus in conjunction with systemic PCP
or MK-801 treatment are required. Finally, it is also possible that
downstream alterations – either intrinsic or extrinsic to the hip-
pocampus – might be involved in altered behavioral responses
in DHI rats. It is clear that there are numerous mechanisms by
which 5,7-DHT-lesions targeting the dorsal hippocampus could
disclose differences in the hyperlocomotor effects of PCP and
MK-801; the exact reasons remain speculative without further
experiments.
Building on our previous 5,7-DHT-lesion studies in rats, our
data highlight an important role for serotonin projections to the
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dorsal hippocampus,most likely from theMnR, in themechanism
of actionof thedissociative anesthetics, PCP,andketamine, butnot
that of MK-801. Given the direction and sensitivity of the behav-
ioral change in dorsal hippocampus lesioned rats, in a normal
state, these compounds may activate MnR-dorsal hippocampus
serotonergic transmission in manner that subsequently serves to
inhibit their net hyperlocomotor effects. The importance of clar-
ifying the pharmacology of the “NMDA receptor antagonists”
in the context of understanding their schizophrenogenic prop-
erties has been emphasized before (Klamer et al., 2005; Gilmour
et al., 2009; Seillier and Giuffrida, 2009), with others ﬁnding that
PCP and ketamine should not be used interchangeably (Gilmour
et al., 2009). Understanding of how the “NMDA receptor antago-
nists” exert their hyperlocomotor effects in rodents is limited and,
despite the seemingly analogous outward expression of locomotor
hyperactivity they elicit, it is clear that the underlying neuro-
chemical mechanisms are different. Elucidating these differences,
particularly with neurotransmitter and brain region speciﬁcity, is
important in the translation of preclinical research using these
compounds in the context of schizophrenia.
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